Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

Abstract

Objective. The aim of the study was to determine the prevalence of cardiometabolic dysregulations and their somatic treatment regimens in a group of psychiatric patients treated with antipsychotics. Methods. In a naturalistic cohort study, baseline cardiometabolic parameters were measured in 543 outpatients. After one year, a second assessment was performed in 220 patients out of the total sample. In addition, it was investigated whether in patients with somatic comorbidities adequate treatment was prescribed. Results. In this cohort, about half of the patients fulfilled the criteria for metabolic syndrome. Only a limited number of patients, however, received pharmacologic treatment for individual risk factors: About 19% for hypercholesterolemia, 26% for hypertension, and 52% for diabetes. Non-treated patients were significantly younger than treated patients. Follow-up data show that the course of the cardiometabolic parameters can be dynamic. Conclusions. Cardiometabolic risk factors are highly prevalent in psychiatric patients treated with antipsychotic drugs. Unfortunately, adequate treatment of cardiometabolic comorbidity in these relatively young patients is seriously hampered. Thus, specific guidelines for psychiatric patients have to be developed taking into account the high cardiovascular risk at a relatively young age and potential pharmacokinetic interactions between psychotropics and somatic compounds. Moreover, integration of psychiatric and physical health care systems for patients with mental disorders is urgently needed.

Key words::

• Cardiometabolic risk factors
• somatic treatment
• severe mental illness
• antipsychotics

Acknowledgments

The authors are indebted to the patients for their co operation and to the members of the nursing staff for completing the records and their management of the patients.

Statement of interest

None of the authors reports conflicts of interest.

This study was partially supported by unrestricted grants from AstraZeneca and Janssen Pharmaceuticals that had, however, no direct relationship with the data as described in the submitted paper.